Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of a Single Dose of PRT-201 Administered Immediately After Arteriovenous Graft Creation in Patients With Chronic Kidney Disease

NCT01001351 is registered in ClinicalTrials.gov with Proteon Therapeutics as lead sponsor.

NCT NCT01001351
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01001351 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of a Single Dose of PRT-201 Administered Immediately After Arteriovenous Graft Creation in Patients With Chronic Kidney Disease
Lead sponsor
Proteon Therapeutics
Phase
Phase 1/2
Overall status
Completed
Start date
September 30, 2009
Completion date
November 30, 2012
Enrollment
89 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease